Acrivon Therapeutics, Inc. (ACRV) AI Stock Analysis

• Market Cap: $52.67M
• Dividend Yield: N/A
• Average Volume (3M): 162.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.25
• Revenue Growth: N/A
• EPS Growth: 10.84%
• Country: US
• Employees: 75
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -2.44
• Shares Outstanding: 31,351,480
• 10 Day Avg. Volume: 413,772
• 30 Day Avg. Volume: 162,777
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 1245.45
• Price to Cash Flow (P/CF): -2.40
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $12.33
• Price Target Upside: 608.62% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

Acrivon's overall stock score is low due to significant financial challenges, including no revenue, increasing losses, and negative cash flows. The weak technical indicators further compound these concerns. However, recent corporate events showing progress in clinical programs and an extended cash runway offer some optimism for future prospects.

Positive Factors

Clinical Trials

Data in endometrial cancer shows strong clinical benefits, with a 35% overall response rate and 80% disease control rate.

Drug Development

Acrivon's OncoSignature assay improves patient selection effectiveness, potentially increasing response rates significantly compared to previous studies.

Financial Stability

The deprioritization of certain programs is expected to have a favorable impact on the company's cash runway, extending it into 2027.

Negative Factors

Financial Outlook

The need for approximately $300M additional financing through 2038 poses a financial risk.

Program Deprioritization

Acrivon is deprioritizing its ovarian and bladder cancer programs due to challenges in patient recruitment and higher efficacy expectations.

Stock Performance

ACRV shares traded down significantly following the clinical update, primarily due to the cessation of the ovarian and bladder programs.

Acrivon Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

How the Company Makes Money

Acrivon Therapeutics, Inc. makes money primarily through the development and commercialization of its targeted oncology therapies. The company generates revenue by advancing its drug candidates through clinical trials with the aim of obtaining regulatory approval and subsequently marketing these therapies. Key revenue streams include potential licensing agreements, partnerships with other pharmaceutical companies, and milestone payments upon achieving specific clinical and regulatory milestones. Additionally, Acrivon may engage in collaborative research and development agreements to enhance its pipeline and broaden its market reach.

Acrivon Therapeutics, Inc. Financial Statement Overview

Summary

Acrivon Therapeutics, Inc. is facing significant financial challenges with no revenue generation and increasing net losses. The company's balance sheet shows a strong equity position, but cash flow is concerning due to heavy reliance on external financing. Overall, the financial health of the company needs improvement to ensure long-term viability.

Income Statement

The company has not generated any revenue over the analyzed period, which is a significant concern. Net income has consistently been negative, and losses have widened over time, with EBIT and EBITDA showing a similar trend. The lack of revenue and increasing losses place the company in a challenging financial position.

Balance Sheet

The company maintains a strong equity position relative to its liabilities, with a high equity ratio. However, the total debt has been managed at a low level, which is a positive sign. Despite these strengths, the consistent net losses reduce the overall value of the equity position.

Cash Flow

Operating cash flow has been consistently negative, indicating that the company is not generating enough cash to cover its operating expenses. Free cash flow is also negative, and the company relies heavily on financing activities to offset cash deficits. This reliance poses potential long-term sustainability risks.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.88M	0.00	0.00	0.00	0.00	0.00
	Gross Profit
1.31M	0.00	-536.00K	-1.09M	-832.00K	-13.00K
	EBIT
-85.30M	-89.20M	-67.24M	-32.66M	-16.18M	-3.17M
	EBITDA
-84.92M	-89.20M	-59.85M	-30.07M	-15.41M	-5.29M
	Net Income Common Stockholders
-76.98M	-80.56M	-60.39M	-29.68M	-16.24M	-5.31M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
99.60M	179.48M	127.46M	127.75M	99.60M	1.58M
	Total Assets
106.59M	196.59M	138.26M	181.23M	106.59M	2.19M
	Total Debt
5.63M	3.65M	4.64M	4.96M	5.63M	58.00K
	Net Debt
-93.97M	-36.17M	-31.37M	-24.56M	-93.97M	-1.52M
	Total Liabilities
130.40M	19.80M	17.07M	10.75M	130.40M	10.60M
	Stockholders Equity
-23.81M	176.79M	121.19M	170.47M	-23.81M	-8.41M
Cash Flow		Free Cash Flow
-63.77M	-68.44M	-43.93M	-32.28M	-14.22M	-2.82M
	Operating Cash Flow
-60.67M	-65.67M	-42.64M	-30.12M	-13.98M	-2.80M
	Investing Cash Flow
-45.65M	-51.77M	50.72M	-141.68M	-238.00K	-15.00K
	Financing Cash Flow
119.66M	121.03M	-1.55M	101.71M	112.22M	2.89M

Acrivon Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.74
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRV, the sentiment is Negative. The current price of 1.74 is below the 20-day moving average (MA) of 4.22, below the 50-day MA of 5.04, and below the 200-day MA of 6.77, indicating a bearish trend. The MACD of -0.85 indicates Positive momentum. The RSI at 19.94 is Positive, neither overbought nor oversold. The STOCH value of 2.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACRV.

Acrivon Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SRPT	68 Neutral	$6.01B	26.21	19.71%	―	52.97%	―
ALNY	55 Neutral	$33.27B	―	-414.62%	―	22.97%	38.54%
BPMC	52 Neutral	$5.49B	―	-31.26%	―	104.04%	87.80%
IONS	49 Neutral	$4.33B	―	-93.03%	―	-10.48%	-18.79%
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
BLUE	36 Underperform	$51.40M	―	-295.35%	―	184.12%	31.92%
ACRV	26 Underperform	$52.67M	―	-54.07%	―	―	10.84%

Acrivon Therapeutics, Inc. Corporate Events

Acrivon Therapeutics Reports 2024 Financial Results and Progress

On March 27, 2025, Acrivon Therapeutics announced its financial results for the fourth quarter and full year 2024, highlighting significant progress in its clinical programs. The company reported promising data from its ACR-368 trials for endometrial cancer, showing a high response rate in heavily pretreated patients, and prioritized this cancer type due to limited treatment options and commercial potential. Additionally, the Phase 1 trial of ACR-2316 is ahead of schedule, with early signs of clinical activity. Acrivon has extended its cash runway into 2027, allowing continued focus on its AP3 platform and drug development efforts.

Acrivon Therapeutics Appoints New Chief Financial Officer

On March 14, 2025, Acrivon Therapeutics announced the appointment of Adam Levy, Ph.D., M.B.A., as Chief Financial Officer effective April 1, 2025. Dr. Levy brings over 25 years of experience in finance and investor relations within the biopharma sector, having previously held senior roles at companies like Zentalis Pharmaceuticals and Gilead Sciences. His appointment follows the departure of Rasmus Holm-Jorgensen, who is stepping down for personal reasons to pursue an opportunity in Europe. This leadership change is not due to any disagreements within the company, and it is expected to strengthen Acrivon’s financial strategy and investor relations.